Company intelligence / Profile preview

Unity Marketing

South San Francisco, California, United Statesunitymarketingonline.com ↗

Ownership: Private
Development stage: Commercial

Overview

UNITY developed senolytic small molecules targeting BCL-xL to treat retinal diseases. Lead candidate UBX1325 showed some sustained vision improvement in DME in Phase 2 studies but failed to match Eylea at key endpoints. Safety profile was favorable. Company has ceased most operations and seeks a partner or buyer for its assets.

Therapeutic areas: Ophthalmology
Modalities: Small moleculeSenolytic medicine
Industry: Biotech

Partnerships

None disclosed as major pharma/biotech partnerships; company actively seeking partners as of May 2025 for asset continuation.

Beyond the preview

Go deeper on Unity Marketing.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unity Marketing.

Explore the full profile